Recent Posts

• EvlaBio raises €21 Million Seed Funding to Develop a Monoclonal Antibody for the Treatment of Left Ventricular Hypertrophy in the Setting of Chronic Kidney Disease
• CasInvent Pharma Secures Next Investment Round with Strong Support from Existing and Local Investors to Advance CK1 Inhibitor Development for Treatment-Resistant Cancer Patients
• First closing of KHAN Technology Transfer Fund II GmbH & Co KG “KHAN-II”
• Norwegian Start-up KinSea Announces First Closing of Seed Financing
• CasInvent Pharma Raises € 1.6 million in Pre-Series A Financing to Support the Development of CK1 Inhibitors for Treatment-Resistant Solid and Hematological Tumours